Therapy results
| Cumulative studies . | Patients, N . | CR, no. (%) . | Relapse, no. (%) . |
|---|---|---|---|
| PCMZL | |||
| Radiotherapy | 132 | 130/132 (99) | 60/130 (46) |
| Excision | 75 | 74/75 (99) | 32/74 (43) |
| Interferon-α | 8 | 8/8 (100) | 2/8 (25) |
| Rituximab intralesional | 9 | 8/9 (89) | 5/8 (62) |
| Rituximab intravenous | 3 | 2/3 (67) | 1/2 (50) |
| Chlorambucil | 14 | 9/14 (64) | 3/9 (33) |
| Antibiotics | 14 | 6/14 (43) | 1/5 (20)* |
| Multiagent chemotherapy | 33 | 28/33 (85) | 16/28 (57) |
| PCFCL | |||
| Radiotherapy | 460 | 457/460 (99) | 216/457 (47) |
| Multiagent chemotherapy | 104 | 88/104 (85) | 42/83 (51)* |
| R-CHOP | 2 | 1/2 (50) | 0/1 (0) |
| Interferon-α | 7 | 7/7 (100) | 2/7 (29) |
| Rituximab intralesional | 12 | 10/12 (83) | 4/10 (40) |
| Rituximab intravenous | 28 | 21/28 (75) | 4/19 (21)* |
| Excision | 93 | 91/93 (98) | 36/91 (40) |
| Chemoradiotherapy | 7 | 7/7 (100) | 1/7 (14) |
| PCLBCL, LT | |||
| Radiotherapy | 101 | 89/101 (88) | 52/89 (58) |
| Multiagent chemotherapy | 32 | 26/32 (81) | 14/24 (58)* |
| R-CHOP | 12 | 11/12 (92) | 1/11 (9)† |
| Chemoradiotherapy | 6 | 4/6 (67) | 1/2 (50)* |
| Rituximab intravenous | 13 | 5/13 (39) | 0/4 (0)* |
| Cumulative studies . | Patients, N . | CR, no. (%) . | Relapse, no. (%) . |
|---|---|---|---|
| PCMZL | |||
| Radiotherapy | 132 | 130/132 (99) | 60/130 (46) |
| Excision | 75 | 74/75 (99) | 32/74 (43) |
| Interferon-α | 8 | 8/8 (100) | 2/8 (25) |
| Rituximab intralesional | 9 | 8/9 (89) | 5/8 (62) |
| Rituximab intravenous | 3 | 2/3 (67) | 1/2 (50) |
| Chlorambucil | 14 | 9/14 (64) | 3/9 (33) |
| Antibiotics | 14 | 6/14 (43) | 1/5 (20)* |
| Multiagent chemotherapy | 33 | 28/33 (85) | 16/28 (57) |
| PCFCL | |||
| Radiotherapy | 460 | 457/460 (99) | 216/457 (47) |
| Multiagent chemotherapy | 104 | 88/104 (85) | 42/83 (51)* |
| R-CHOP | 2 | 1/2 (50) | 0/1 (0) |
| Interferon-α | 7 | 7/7 (100) | 2/7 (29) |
| Rituximab intralesional | 12 | 10/12 (83) | 4/10 (40) |
| Rituximab intravenous | 28 | 21/28 (75) | 4/19 (21)* |
| Excision | 93 | 91/93 (98) | 36/91 (40) |
| Chemoradiotherapy | 7 | 7/7 (100) | 1/7 (14) |
| PCLBCL, LT | |||
| Radiotherapy | 101 | 89/101 (88) | 52/89 (58) |
| Multiagent chemotherapy | 32 | 26/32 (81) | 14/24 (58)* |
| R-CHOP | 12 | 11/12 (92) | 1/11 (9)† |
| Chemoradiotherapy | 6 | 4/6 (67) | 1/2 (50)* |
| Rituximab intravenous | 13 | 5/13 (39) | 0/4 (0)* |